It is currently active but not recruiting in three clinical studies for solid tumor, breast cancer (HER2+ metastatic BC) and metastatic breast cancer (HER2+ patients with recurrent stage IV cancer who have had at least two previous HER2-directed treatments) [111,112,113]. This evidence concerns the gene ERBB2 and cancer.